Shenzhen TargetRx Raises $50M in Series C Financing for Global Clinical Trials
China-based Shenzhen TargetRx, Inc., a developer of small-molecule kinase inhibitors, has announced the completion of...
TargetRx
Jiangsu Simcere Acquires Exclusive Rights to TargetRx’s TGRX-326 in Licensing Deal
SHENZHEN—Shenzhen TargetRx, Inc., a leading developer of small-molecule kinase inhibitors, has entered into a licensing...
Shenzhen TargetRx’s TGRX-678 Set to Receive Breakthrough Therapy Designation for CML-AP
Shenzhen TargetRx, Inc., a China-based developer of small-molecule kinase inhibitors, is poised to receive breakthrough...
Shenzhen TargetRx Raises Hundreds of Millions in Series B Financing for Drug Development
China-based Shenzhen TargetRx, Inc., a developer of small-molecule kinase inhibitors, reportedly raised “hundreds of millions”...